Sanofi has agreed to purchase its own shares worth €2bn ($2.08bn), part of a $5.1bn share buyback initiative in 2025.

The deal will diversify the French beauty giant’s funding sources at a time when the industry is undergoing a slowdown.

French pharmaceutical and healthcare company Sanofi on Friday announced a share buyback plan worth up to €2 billion ($2.08 ...

Immunology superstar Dupixent, which first brought Regeneron and Sanofi together in 2007, has entered its megablockbuster era ...

French pharmaceutical company Sanofi said on Monday that it plans to buy back shares from cosmetics firm L'Oréal. Sanofi said ...

Saudi Arabia is now shifting toward localized production, a move that will significantly enhance national drug security and ...

While Sanofi’s immunology megablockbuster Dupixent predictably dominated the company’s sales charts in 2024, a new golden ...

According to the lawsuit, Sanofi has failed to provide partner Regeneron adequate information regarding the sales of Dupixent ...

French healthcare company Sanofi announced on Friday a share buyback plan worth up to 2 billion euros ($2.1 billion), which ...

Amazon Music and WPP unveiled Louder Than Cancer, an effort uniting top global artists to harness the power of music in recognition of World Cancer Day with creative leadership from WPP’s Grey Health, ...

Analysts fell to the sidelines weighing in on Sumitomo Dainippon Pharma Co (DNPUF – Research Report) and Sanofi (SNYNF – Research Report) with ...

AdvanCell has secured $112 million in a Sanofi Ventures-backed series C funding round as the Australian radiopharma company ...